REPOST: CA-125: To Monitor or Not to Monitor?: Evidence Against Monitoring CA-125

 Blogger's Note: Medscape requires registration (free)

CA-125: To Monitor or Not to Monitor?: Evidence Against Monitoring CA-125

 From Medscape Hematology-Oncology

CA-125: To Monitor or Not to Monitor?

For Ovarian Cancer Patients in Remission

Gordon Rustin, MD; Beth Y. Karlan, MD; Maurie Markman, MD

Authors and Disclosures

Posted: 03/08/2012

Commentary: Early versus delayed treatment of relapsed ovarian cancer : The Lancet (re: Rustin trial early vs delayed treatments/survival)

full free access: Rustin et al: Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial : The Lancet

Note: full free access is available/registration (free) is required to view

Oncology Videos ASCO 2009: Rustin trial UK: Treatment based on rising CA125 blood levels does not improve survival for ovarian cancer